IMDS News Just Out . . .
FORT LAUDERDALE, Fla., Feb. 23 /PRNewswire/ -- Imaging Diagnostic Systems
Inc., (OTC Bulletin Board: IMDS) announced today that it was granted approval
on February 8 to conduct clinical studies for the use of Diagnostic Breast
Imaging (CTLM)(TM) with Indocyanine Green contrast agent (ICG). The studies,
which are limited to 50 subjects, will begin once the Company has obtained
approval from the Institutional Review Boards (IRB) of the medical
institutions that have been selected by Imaging Diagnostic Systems.
The goal of the study is to investigate the use of fluorescent compounds,
such as ICG, to determine if it increases the imaging sensitivity of the
CTLM(TM). The FDA approved contrast agent, ICG, will be used in this study to
enhance the presence of a suspicious lesion. "In these preliminary studies,
we hope to demonstrate the potential of contrast agents together with the
CTLM(TM) device to more accurately predict the outcome of a biopsy and use
this as an advantage in diagnosing breast abnormalities," said Richard Grable,
CEO.
Imaging Diagnostic Systems has developed the world's first patented laser-
based breast imaging device, known as the CTLM(TM), that utilizes state-of-
the-art laser technology and patented computed algorithms that create
contiguous cross sectional slice images of the breast without the use of
breast compression or x-rays.
SOURCE Imaging Diagnostic Systems, Inc.
-0- 02/23/2000
/CONTACT: Deborah O'Brien of Imaging Diagnostic Systems, Inc.,
954-581-9800/
/Web site: imds.com / |
